 <h1>Carboplatin Novaplus Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>carboplatin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about carboplatin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Carboplatin Novaplus.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to carboplatin: intravenous powder for solution, intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution; Powder for Solution)</p><p>Bone marrow suppression with carboplatin is dose-related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin administration.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, carboplatin (the active ingredient contained in Carboplatin Novaplus) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.</p><p>Check with your doctor as soon as possible if any of the following side effects occur while taking carboplatin:</p><p>
<i>More common</i>
</p><ul>
<li>Pain at place of injection</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blood in urine or stools</li>
<li>cough or hoarseness, accompanied by fever or chills</li>
<li>fever or chills</li>
<li> lower back or side pain, accompanied by fever or chills</li>
<li> numbness or tingling in fingers or toes</li>
<li>painful or difficult urination, accompanied by fever or chills</li>
<li> pinpoint red spots on skin</li>
<li>skin rash or itching </li>
<li>unusual bleeding or bruising</li>
<li> unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blurred vision</li>
<li>ringing in ears</li>
<li>sores in mouth and on lips</li>
<li>wheezing </li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of carboplatin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Nausea and vomiting</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Constipation or diarrhea</li>
<li>loss of appetite </li>
</ul><p>This medicine may cause a temporary loss of hair in some people. After treatment with carboplatin has ended, normal hair growth should return.</p><p>
<!-- end intravenous powder for solution, intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carboplatin: intravenous powder for injection, intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (98%), neutropenia (97%), anemia (91%), thrombocytopenia (70%), bleeding (10%)</p>
<p><b>Rare</b> (less than 0.1%): Febrile neutropenia </p>
<p><b>Frequency not reported</b>: Bone marrow failure, hemolytic-uremic syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (93%), vomiting (84%), adverse GI effects (50%), abdominal pain</p>
<p><b>Common</b> (1% to 10%): Mucositis, diarrhea, constipation</p>
<p><b>Frequency not reported</b>: Stomatitis, pancreatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Central neurotoxicity (26%), peripheral neuropathy (15%)</p>
<p><b>Common</b> (1% to 10%): Other sensory side effects, paresthesia, decrease of osteotendinous reflexes, sensory disturbance, dysgeusia</p>
<p><b>Frequency not reported</b>: Cerebrovascular accident, reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alkaline phosphatase elevations (29%), SGOT elevations (20%), aspartate aminotransferase increased, liver function test abnormal</p>
<p><b>Common</b> (1% to 10%): Bilirubin elevations<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Blood urea elevations (17%), creatinine renal clearance decreased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (44%), asthenia (41%), ototoxicity (12%)</p>
<p><b>Common</b> (1% to 10%): Asthenia</p>
<p><b>Frequency not reported</b>: Malaise<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity, anaphylactoid type reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Magnesium loss (61%), potassium loss (16%), calcium loss (16%), sodium loss (10%)</p>
<p><b>Rare</b> (less than 0.1%): Hyponatremia </p>
<p><b>Frequency not reported</b>: Dehydration, anorexia, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Visual disturbance (including rare cases of loss of vision)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (14%)</p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site necrosis, injection site reaction, injection site extravasation, injection site erythema</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal disorder<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urogenital disorder<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Neoplasms (e.g., benign, malignant, unspecified) including cysts and polyps<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory disorder, interstitial lung disease, bronchospasm</p>
<p><b>Frequency not reported</b>: Pneumonia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiovascular disorder</p>
<p><b>Frequency not reported</b>: Cardiac failure, embolism, hypertension, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (49%), skin disorder </p>
<p><b>Frequency not reported</b>: Urticaria, rash, erythema, pruritus<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_2">2. "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_3">3. Kerr DJ, Lewis C, O'Neill B, et al "The myelotoxicity of carboplatin is influenced by the time of its administration." Hematol Oncol 8 (1990): 59-63</p><p id="ref_4">4. "Product Information. Carboplatin (CARBOplatin)." Sun Pharmaceutical Industries, Cranbury, NJ. </p><p id="ref_5">5. McDonald BR, Kirmani S, Vasquez M, Mehta R "Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature." Am J Med 90 (1991): 386-91</p><p id="ref_6">6. Deray G, Ben-Othman T, Brillet G, Baumelou B, Gabarre J, Baumelou A, Binet JL, Jacobs C "Carboplatin-induced acute renal failure." Am J Nephrol 10 (1990): 431-2</p><p id="ref_7">7. Mulder PO, Sleijfer DT, de Vries EG, Uges DR, Mulder NH "Renal dysfunction following high-dose carboplatin treatment." J Cancer Res Clin Oncol 114 (1988): 212-4</p><p id="ref_8">8. Chevreau C,  Thomas F,  Couteau C,  Dalenc F,  Mourey L,  Chatelut E "Ototoxicity of high-dose Carboplatin." J Clin Oncol 23 (2005): 3649-50</p><p id="ref_9">9. Windom HH, McGuire WP, Hamilton RG, Adkinson NF "Anaphylaxis to carboplatin: a new platinum chemotherapeutic agent." J Allergy Clin Immunol Oct (1992): 681-3</p><p id="ref_10">10. Broome CB, Schiff RI, Friedman HS "Successful desentization to carboplatin in patients with systemic hypersensitivity reactions." Med Pediatr Oncol 26 (1996): 105-10</p><p id="ref_11">11. Tonkin KS, Rubin P, Levin L "Carboplatin hypersensitivity: case reports and review of the literature." Eur J Cancer 29a (1993): 1356-7</p><p id="ref_12">12. Planner RS, Weerasiri T, Timmins D, Grant P "Hypersensitivity reactions to carboplatin." J Natl Cancer Inst 83 (1991): 1763-4</p><p id="ref_13">13. Weidmann B, Mulleneisen N, Bojko P, Niederle N "Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management." Cancer 73 (1994): 2218-22</p><p id="ref_14">14. Sood AK, Gelder MS, Huang SW, Morgan LS "Anaphylaxis to carboplatin following multiple previous uncomplicated courses." Gynecol Oncol 57 (1995): 131-2</p><p id="ref_15">15. O'Brien MER, Tonge K, Blake P, et al "Blindness associated with high-dose carboplatin." Lancet 339 (1991): 558</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Carboplatin Novaplus (carboplatin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: alkylating agents</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Paraplatin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cancer</li>
<li>Cervical Cancer</li>
<li>Ovarian Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carboplatin: intravenous powder for injection, intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (98%), neutropenia (97%), anemia (91%), thrombocytopenia (70%), bleeding (10%)</p><p><b>Rare</b> (less than 0.1%): Febrile neutropenia </p><p><b>Frequency not reported</b>: Bone marrow failure, hemolytic-uremic syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (93%), vomiting (84%), adverse GI effects (50%), abdominal pain</p><p><b>Common</b> (1% to 10%): Mucositis, diarrhea, constipation</p><p><b>Frequency not reported</b>: Stomatitis, pancreatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Central neurotoxicity (26%), peripheral neuropathy (15%)</p><p><b>Common</b> (1% to 10%): Other sensory side effects, paresthesia, decrease of osteotendinous reflexes, sensory disturbance, dysgeusia</p><p><b>Frequency not reported</b>: Cerebrovascular accident, reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alkaline phosphatase elevations (29%), SGOT elevations (20%), aspartate aminotransferase increased, liver function test abnormal</p><p><b>Common</b> (1% to 10%): Bilirubin elevations<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Blood urea elevations (17%), creatinine renal clearance decreased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (44%), asthenia (41%), ototoxicity (12%)</p><p><b>Common</b> (1% to 10%): Asthenia</p><p><b>Frequency not reported</b>: Malaise<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity, anaphylactoid type reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Magnesium loss (61%), potassium loss (16%), calcium loss (16%), sodium loss (10%)</p><p><b>Rare</b> (less than 0.1%): Hyponatremia </p><p><b>Frequency not reported</b>: Dehydration, anorexia, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Visual disturbance (including rare cases of loss of vision)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (14%)</p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site necrosis, injection site reaction, injection site extravasation, injection site erythema</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal disorder<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urogenital disorder<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Neoplasms (e.g., benign, malignant, unspecified) including cysts and polyps<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory disorder, interstitial lung disease, bronchospasm</p><p><b>Frequency not reported</b>: Pneumonia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiovascular disorder</p><p><b>Frequency not reported</b>: Cardiac failure, embolism, hypertension, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (49%), skin disorder </p><p><b>Frequency not reported</b>: Urticaria, rash, erythema, pruritus<sup>[Ref]</sup></p><p id="ref_1">1. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_2">2. "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_3">3. Kerr DJ, Lewis C, O'Neill B, et al "The myelotoxicity of carboplatin is influenced by the time of its administration." Hematol Oncol 8 (1990): 59-63</p><p id="ref_4">4. "Product Information. Carboplatin (CARBOplatin)." Sun Pharmaceutical Industries, Cranbury, NJ. </p><p id="ref_5">5. McDonald BR, Kirmani S, Vasquez M, Mehta R "Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature." Am J Med 90 (1991): 386-91</p><p id="ref_6">6. Deray G, Ben-Othman T, Brillet G, Baumelou B, Gabarre J, Baumelou A, Binet JL, Jacobs C "Carboplatin-induced acute renal failure." Am J Nephrol 10 (1990): 431-2</p><p id="ref_7">7. Mulder PO, Sleijfer DT, de Vries EG, Uges DR, Mulder NH "Renal dysfunction following high-dose carboplatin treatment." J Cancer Res Clin Oncol 114 (1988): 212-4</p><p id="ref_8">8. Chevreau C,  Thomas F,  Couteau C,  Dalenc F,  Mourey L,  Chatelut E "Ototoxicity of high-dose Carboplatin." J Clin Oncol 23 (2005): 3649-50</p><p id="ref_9">9. Windom HH, McGuire WP, Hamilton RG, Adkinson NF "Anaphylaxis to carboplatin: a new platinum chemotherapeutic agent." J Allergy Clin Immunol Oct (1992): 681-3</p><p id="ref_10">10. Broome CB, Schiff RI, Friedman HS "Successful desentization to carboplatin in patients with systemic hypersensitivity reactions." Med Pediatr Oncol 26 (1996): 105-10</p><p id="ref_11">11. Tonkin KS, Rubin P, Levin L "Carboplatin hypersensitivity: case reports and review of the literature." Eur J Cancer 29a (1993): 1356-7</p><p id="ref_12">12. Planner RS, Weerasiri T, Timmins D, Grant P "Hypersensitivity reactions to carboplatin." J Natl Cancer Inst 83 (1991): 1763-4</p><p id="ref_13">13. Weidmann B, Mulleneisen N, Bojko P, Niederle N "Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management." Cancer 73 (1994): 2218-22</p><p id="ref_14">14. Sood AK, Gelder MS, Huang SW, Morgan LS "Anaphylaxis to carboplatin following multiple previous uncomplicated courses." Gynecol Oncol 57 (1995): 131-2</p><p id="ref_15">15. O'Brien MER, Tonge K, Blake P, et al "Blindness associated with high-dose carboplatin." Lancet 339 (1991): 558</p><h2>More about Carboplatin Novaplus (carboplatin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: alkylating agents</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cancer</li>
<li>Cervical Cancer</li>
<li>Ovarian Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>